	US 11,814,380 B2
	Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors
Juergen Ramharter, Vienna (AT); Christiane Kofink, Perchtoldsdorf (AT); Heinz Stadtmueller, Vienna (AT); Tobias Wunberg, Hinterbruehl (AT); Marco Hans Hofmann, Vienna (AT); Anke Baum, Moedling (AT); Michael Gmachl, Vienna (AT); Dorothea Ingrid Rudolph, Vienna (AT); Fabio Savarese, Maria Enzersdorf (AT); Markus Ostermeier, Biberach an der Riss (DE); Markus Frank, Ulm (DE); Annika Gille, Ulm (DE); Stefan Goepper, Biberach an der Riss (DE); Marco Santagostino, Mittelbiberach (DE); and Julian Wippich, Biberach (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Sep. 24, 2020, as Appl. No. 17/030,603.
Application 17/030,603 is a continuation of application No. 16/226,824, filed on Dec. 20, 2018, granted, now 10,829,487.
Claims priority of application No. 17209865 (EP), filed on Dec. 21, 2017.
Prior Publication US 2021/0009588 A1, Jan. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61P 35/00 (2006.01); C07D 471/08 (2006.01); C07D 519/00 (2006.01); C07D 453/02 (2006.01); A61K 45/06 (2006.01)

CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01); C07D 453/02 (2013.01); C07D 471/08 (2013.01); C07D 519/00 (2013.01); A61K 45/06 (2013.01)]

14 Claims

1. A compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof.